αvβ3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26

Nestić, Davor; Uil, Taco G.; Ma, Jiangtao; Roy, Subhasish; Vellinga, Jort; Baker, Andrew H.; Custers, Jerome; Majhen, Dragomira

doi:10.1128/jvi.01474-18

Cited by 32 publications

(41 citation statements)

References 45 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Oncolytic virus (OV) therapy is a novel and promising therapeutic approach for tumors that involves selectively infecting and killing tumor cells. Prior research studies demonstrated that αvβ3 integrin and nectin-1 are required for efficient infection of cells by herpesvirus and adenovirus, respectively 7,8 , and the underlying mechanism may involve OV-induced cell destruction by cancerspecific genetic alteration, as well as sequential virus release and viral infection. It was first reported that tumors could be inhibited or shrunk in patients with cervical cancer and rabies virus positivity 9 .…”

Section: Introductionmentioning

confidence: 99%

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas

Zhang

Liu

2020

Cell Death Dis

View full text Add to dashboard Cite

Glioblastoma (GBM) is an immunosuppressive, lethal brain tumor. Despite advances in molecular understanding and therapies, the clinical benefits have remained limited, and the life expectancy of patients with GBM has only been extended to~15 months. Currently, genetically modified oncolytic viruses (OV) that express immunomodulatory transgenes constitute a research hot spot in the field of glioma treatment. An oncolytic virus is designed to selectively target, infect, and replicate in tumor cells while sparing normal tissues. Moreover, many studies have shown therapeutic advantages, and recent clinical trials have demonstrated the safety and efficacy of their usage. However, the therapeutic efficacy of oncolytic viruses alone is limited, while oncolytic viruses expressing immunomodulatory transgenes are more potent inducers of immunity and enhance immune cell-mediated antitumor immune responses in GBM. An increasing number of basic studies on oncolytic viruses encoding immunomodulatory transgene therapy for malignant gliomas have yielded beneficial outcomes. Oncolytic viruses that are armed with immunomodulatory transgenes remain promising as a therapy against malignant gliomas and will undoubtedly provide new insights into possible clinical uses or strategies. In this review, we summarize the research advances related to oncolytic viruses that express immunomodulatory transgenes, as well as potential treatment pitfalls in patients with malignant gliomas. Facts Open questions 1. Can the immune system attack and engulf exogenous viruses? 2. Are glioma stem cells resistant to viral therapy? 3. Can the presence of nontumor cells such as tumor stroma cells impede the spread of oncolytic viruses? 4. In personalized medicine, should potential challenges be considered for the treatment of patients with malignant gliomas?

show abstract

Section: Introductionmentioning

confidence: 99%

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas

Zhang

Liu

2020

Cell Death Dis

View full text Add to dashboard Cite

show abstract

“…Importantly, the primary cellular receptor usage for these species D Ads has not been fully determined and remains controversial in the literature. For example, some studies have suggested that Ad26 uses CD46 as a cellular receptor [5,16,22,23] while other studies challenge the utilization of CD46 and instead suggest CAR [37,38], αvβ3 integrin [39], scavenger receptor SR-A6 [40], sialic acid-bearing glycans [41], or another uncharacterized receptor as the primary receptor. Receptor usage for Ad48 also remains controversial [5,16,23,38,42] while receptor usage for Ad28 and Ad45 has not been explored in depth [20,23].…”

Section: Discussionmentioning

confidence: 99%

Species D Adenoviruses as Oncolytic Viral Vectors

Bullard

Corder

Weaver

2020

Viruses

View full text Add to dashboard Cite

Oncolytic adenoviruses (Ad) have shown promising results in the therapeutic treatment of cancer. Ad type 5 (Ad5) is the most extensively utilized Ad type. However, several limitations exist to using Ad5 as an oncolytic virus, including high levels of anti-Ad5 neutralizing antibodies in the population, binding of the Ad5 hexon to blood coagulation factor X leading to liver sequestration and toxicity, and reduced expression of the primary receptor CAR on many tumors. Here, we use in vitro methods to explore the oncolytic potential of four alternative Ad types (Ad26, 28, 45, and 48) belonging to the species D Ad subgroup and developed replication-competent species D Ads expressing the human sodium iodide symporter protein (hNIS) for combination radiovirotherapy. We evaluated the species D Ad vectors transduction, replication, cytotoxicity, and gene expression in six different cancer cell lines. Species D Ads showed the greatest transduction and cytotoxic killing in the SKBR3 breast cancer cells, followed by 293, A549, and HepG2 cells, however the cytotoxicity was less than the wild type Ad5 virus. In contrast, species D Ads showed limited transduction and cytotoxicity in the Hela and SKOV3 cancer cell lines. These species D Ad vectors also successfully expressed the hNIS gene during infection leading to increased iodide uptake in multiple cancer cell lines. These results, the low seroprevalence of anti-species D antibodies, and the lack of binding to blood coagulation FX, support further exploration of species D Ads as alternative oncolytic adenoviruses against multiple types of cancer.

show abstract

“…Ma and colleagues in 2018 reported that IRE1α act as an endoplasmic reticulum stress sensor, leading to increased expression of negative regulators of JAK/STAT, suppressor of cytokine signaling (SOCS)-1 and SOCS-3 in response to CoVs transmissible gastroenteritis virus. Therefore, IRE1α may be a novel target against COVID-19 and requiring further studies [ 126 ]. At the moment the present review is being written, it has not been reported targeting IRE1α to confirm its therapeutic effects in COVID-19 infection.…”

Section: Jak/stat Inhibitorsmentioning

confidence: 99%

Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection

et al. 2021

View full text Add to dashboard Cite

Objective Coronavirus disease 2019 (COVID-19) is a world-wide pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). To date, treatment of severe COVID-19 is far from clear. Therefore, it is urgent to develop an effective option for the treatment of patients with COVID-19. Most patients with severe COVID-19 exhibit markedly increased serum levels of pro-inflammatory cytokines, including interferon (IFN)-α, IFN-γ, and interleukin (IL)-1β. Immunotherapeutic strategies have an important role in the suppression of cytokine storm and respiratory failure in patients with COVID-19. Methods A systematic search in the literature was performed in PubMed, Scopus, Embase, Cochrane Library, Web of Science, as well as Google Scholar preprint database using all available MeSH terms for Coronavirus, SARS-CoV-2, anti-rheumatoid agents, COVID-19, cytokine storm, immunotherapeutic drugs, IFN, interleukin, JAK/STAT inhibitors, MCP, MIP, TNF. Results Here, we first review common complications of COVID-19 patients, particularly neurological symptoms. We next explain host immune responses against COVID-19 particles. Finally, we summarize the existing experimental and clinical immunotherapeutic strategies, particularly anti-rheumatoid agents and also plasma (with a high level of gamma globulin) therapy for severe COVID-19 patients. We discuss both their therapeutic effects and side effects that should be taken into consideration for their clinical application. Conclusion It is suggested that immunosuppressants, such as anti-rheumatoid drugs, could be considered as a potential approach for the treatment of cytokine storm in severe cases of COVID-19. One possible limitation of immunosuppressant therapy is their inhibitory effects on host anti-viral immune response. So, the appropriate timing of administration should be carefully considered.

show abstract

αvβ3 Integrin Is Required for Efficient Infection of Epithelial Cells with Human Adenovirus Type 26

Cited by 32 publications

References 45 publications

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas

Advances and potential pitfalls of oncolytic viruses expressing immunomodulatory transgene therapy for malignant gliomas

Species D Adenoviruses as Oncolytic Viral Vectors

Pharmacological mechanism of immunomodulatory agents for the treatment of severe cases of COVID-19 infection

Contact Info

Product

Resources

About